NCT06744712Not yet recruiting
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets. PGx testing uses an individual's genetic factors, such as single nucleotide polymorphisms (SNPs), to personalize therapy or dose a selection of medications. PGx testing has traditionally been used to test single genes, but there are now platforms allowing a panel of genes to be tested at once. To date there has not been a comprehensive screening of pediatric oncology patients to determine the prevalence of genetic variants that may affect anticancer therapy and supportive care medications. This study would allow us to summarize the frequency of clinically relevant gene-drug interactions and actionable genetic polymorphisms in pediatric oncology patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 27 Nov 2024
- Start date
- Nov 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Childhood cancers
- NCT number
- NCT06744712
What you commit to
- Study type: Interventional
- Planned participants: 130
- From Nov 2026 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received bone marrow transplant or planning to receive as part of initial upfront therapy for a malignant condition.
- Prior history of tissue or organ transplant.
Other illness
- Anti-cancer therapy has already been initiated. Note: Enrollment after initiation of intrathecal chemotherapy will be allowed.
Who the study is looking for
- Written informed consent and HIPAA authorization for release of personal health information, and assent when applicable, from the participant, parent or legal guardian.
- Age ≤ 26 years at the time of consent.
- Newly diagnosed with a malignancy and planning to undergo anti-cancer therapy; or bone marrow transplant candidate with a non-malignant diagnosis who has not yet undergone myeloablative conditioning regimen.
Age in the registry: - to 26 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Levine Childrens Hospital Pediatric Cancer and Blood Disorders Coordinator of this site? Confirm its status | Charlotte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.